Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-ARMOR: Dapagliflozin for Prevention of Platinum-Induced Kidney Injury
NCT07018622Phase 2Recruiting
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in cisplatin-induced nephrotoxicity (CIN), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Started May 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT07018622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018622.